Role of the Beta Catenin Destruction Complex in Mediating Chemotherapy-Induced Senescence-Associated Secretory Phenotype

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Basu, Dipanjan ^a   Reyes Mugica, Miguel ^a   Rebbaa, Abdelhadi ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTINEOPLASTIC AGENT; BELINOSTAT; BETA CATENIN; BORTEZOMIB; CYTOKINE; DOXORUBICIN; GROWTH FACTOR; LIGAND; PYRVINIUM EMBONATE; RAPAMYCIN; UNCLASSIFIED DRUG; WNT PROTEIN; XAV 939;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BETA CATENIN DESTRUCTION COMPLEX; CANCER CELL; CANCER INVASION; CANCER RESISTANCE; CELL AGING; CELL MIGRATION; CELLULAR SECRETION; CHEMOTHERAPY INDUCED SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; SENESCENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; AXIN SIGNALING COMPLEX; BIOLOGICAL MARKERS; CELL AGING; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIGANDS; PHENOTYPE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84871303916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052188     Document Type: Article

References (40)

1. Shay JW, Roninson IB, (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23: 2919-2933.
2. Hayflick L, Moorhead PS, (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585-621.
3. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, et al. (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59: 3761-3767.
4. Robles SJ, Adami GR, (1998) Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16: 1113-1123.
5. Chang BD, Swift ME, Shen M, Fang J, Broude EV, et al. (2002) Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 99: 389-394.
6. Coppe JP, Desprez PY, Krtolica A, Campisi J, (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
7. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, et al. (2011) SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene.
8. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, et al. (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133: 1019-1031.
9. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, et al. (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66: 794-802.
10. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
11. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, et al. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
12. Pazolli E, Alspach E, Milczarek A, Prior J, Piwnica-Worms D, et al. (2012) Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res 72: 2251-2261.
13. Freund A, Patil CK, Campisi J, (2011) p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 30: 1536-1548.
14. Laberge RM, Awad P, Campisi J, Desprez PY, (2012) Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron 5: 39-44.
15. Laberge RM, Zhou L, Sarantos MR, Rodier F, Freund A, et al. (2012) Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell.
16. Lyden D, Welch DR, Psaila B (2011) Cancer metastasis: biologic basis and therapeutics. Cambridge: Cambridge University Press.
17. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, et al. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280: 596-599.
18. Valvezan AJ, Zhang F, Diehl JA, Klein PS, (2012) Adenomatous polyposis coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity. J Biol Chem 287: 3823-3832.
19. Xu C, Kim NG, Gumbiner BM, (2009) Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 8: 4032-4039.
20. Doble BW, Woodgett JR, (2007) Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 185: 73-84.
21. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, et al. (2008) Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106: 1855-1865.
22. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, et al. (2012) beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med.
23. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT, (2003) Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol 13: 680-685.
24. Rebbaa A, Chou PM, Mirkin BL, (2001) Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 7: 393-400.
25. Zheng X, Chou PM, Mirkin BL, Rebbaa A, (2004) Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res. 64: 1773-1780.
26. Mirkin BL, Clark S, Zheng X, Chu F, White BD, et al. (2005) Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24: 4965-4974.
27. Roninson IB, (2003) Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715.
28. Rebbaa A, Zheng X, Chou PM, Mirkin BL, (2003) Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22: 2805-2811.
29. Schmitt CA, (2007) Cellular senescence and cancer treatment. Biochim Biophys Acta 1775: 5-20.
30. Tetsu O, McCormick F, (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
31. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, et al. (2011) beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 108: 19204-19209.
32. Ji H, Wang J, Nika H, Hawke D, Keezer S, et al. (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36: 547-559.
33. Jin T, George Fantus I, Sun J, (2008) Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal 20: 1697-1704.
34. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, et al. (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461: 614-620.
35. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, et al. (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 6: 829-836.
36. Liang CC, Park AY, Guan JL, (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
37. Yu DH, Macdonald J, Liu G, Lee AS, Ly M, et al. (2008) Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One 3: e3951.
38. Esumi H, Lu J, Kurashima Y, Hanaoka T, (2004) Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95: 685-690.
39. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE, (2012) Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15: 50-61.
40. Kendziorra E, Ahlborn K, Spitzner M, Rave-Frank M, Emons G, et al. (2011) Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 32: 1824-1831.